GlassScriptPhysician profile
Brian P Callahan
NPI 1982750576
$746.29
in general payments reported to CMS, 2019-2025
15 companies · $199 in 2025
The $199 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $15.40 · 2021: $115 · 2022: $15.08 · 2023: $96.95 · 2024: $135 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $430.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $356.26 | 2019-2024 | Patient Trial Kit |
| Abbvie INC. | $77.59 | 2025 | |
| Servier Pharmaceuticals LLC | $52.03 | 2025 | |
| Argenx US, INC. | $44.35 | 2023-2024 | Vyvgart Hytrulo |
| Ucb, INC. | $37.42 | 2024 | Rystiggo, Briviact |
| Eisai INC. | $36.23 | 2024-2025 | |
| Sk Life Science, INC. | $23.71 | 2023 | |
| Vanda Pharmaceuticals INC. | $21.01 | 2025 | Ponvory |
| Impel Pharmaceuticals INC. | $19.71 | 2023 | Trudhesa |
| Alexion Pharmaceuticals, INC. | $17.73 | 2024 | Ultomiris |
| Biogen, INC. | $15.60 | 2025 | Spinraza |
| Amneal Pharmaceuticals LLC | $15.49 | 2023 | Lyvispah |
| Neurocrine Biosciences, INC. | $15.43 | 2024 | Ingrezza |
| Merz Pharmaceuticals, LLC | $13.73 | 2025 | Xeomin, Ampyra, Inbrija |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,884,877.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Callahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.